Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM4XMF7)

Drug Name
LY2606368 Drug Info
Synonyms
prexasertib; Prexasertib; 1234015-52-1; UNII-820NH671E6; LY-2606368; 820NH671E6; Prexasertib [USAN]; 5-((5-(2-(3-aminopropoxy)-6-methoxyphenyl)-1H-pyrazol-3-yl)amino)pyrazine-2-carbonitrile; 5-({5-[2-(3-aminopropoxy)-6-methoxyphenyl]-1H-pyrazol-3-yl}amino)pyrazine-2-carbonitrile; 5-[[5-[2-(3-aminopropoxy)-6-methoxyphenyl]-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile; SCHEMBL1975451; GTPL9549; SCHEMBL19457660; SCHEMBL18989301; CHEMBL3544911; EX-A758; DOTGPNHGTYJDEP-UHFFFAOYSA-N; AOB87325; ZINC95837013
Indication
Disease Entry ICD 11 Status REF
Ovarian cancer 2C73 Phase 2 [1]
Small-cell lung cancer 2C25.Y Phase 2 [1]
Head and neck cancer 2D42 Phase 1 [1]
Solid tumour/cancer 2A00-2F9Z Phase 1 [2]
Squamous cell anal carcinoma 2C00.3 Phase 1 [3]
Cross-matching ID
PubChem CID
46700756
CAS Number
CAS 1234015-52-1
TTD Drug ID
DM4XMF7

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Patented Agent(s)
Discontinued Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Checkpoint kinase-1 (CHK1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
LY2603618 DMCXRZF Pancreatic cancer 2C10 Phase 2 [4]
UCN-01 DMUNJZB Non-small-cell lung cancer 2C25.Y Phase 2 [5]
SCH-900776 DM67EMK Solid tumour/cancer 2A00-2F9Z Phase 2 [6]
LY2880070 DMADEHZ Solid tumour/cancer 2A00-2F9Z Phase 1/2 [7]
RG7741 DMK6P9J Lymphoma 2A80-2A86 Phase 1 [8]
GDC-0425 DMDZ26X Lymphoma 2A80-2A86 Phase 1 [9]
AZD7762 DM1FW0C Solid tumour/cancer 2A00-2F9Z Phase 1 [10]
MK-8776 DMAS1RB Hodgkin lymphoma 2B30 Phase 1 [11]
Diamidothiazole derivative 1 DM02V5Q N. A. N. A. Patented [12]
XL844 DMHTG38 Solid tumour/cancer 2A00-2F9Z Discontinued in Phase 1 [13]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Checkpoint kinase-1 (CHK1) TTTU902 CHK1_HUMAN Inhibitor [1]

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 Clinical pipeline report, company report or official report of Eli Lilly.
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 Characterization and preclinical development of LY2603618: a selective and potent Chk1 inhibitor. Invest New Drugs. 2014 Apr;32(2):213-26.
5 Characterization of an inhibitory dynamic pharmacophore for the ERCC1-XPA interaction using a combined molecular dynamics and virtual screening app... J Mol Graph Model. 2009 Sep;28(2):113-30.
6 Targeting the replication checkpoint using SCH 900776, a potent and functionally selective CHK1 inhibitor identified via high content screening. Mol Cancer Ther. 2011 Apr;10(4):591-602.
7 A phase Ib study of oral Chk1 inhibitor LY2880070 in combination with gemcitabine in patients with advanced or metastatic cancer. Journal of Clinical Oncology 38, no. 15_suppl (May 20, 2020) 3581-3581.
8 National Cancer Institute Drug Dictionary (drug id 730054).
9 Quantitative assessment of BCL-2:BIM complexes as a pharmacodynamic marker for venetoclax (ABT-199).
10 Clinical pipeline report, company report or official report of AstraZeneca (2009).
11 Chk1 Inhibitor MK-8776 Restores the Sensitivity of Chemotherapeutics in P-glycoprotein Overexpressing Cancer Cells. Int J Mol Sci. 2019 Aug 22;20(17):4095.
12 Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70.
13 Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.